Beclomethasone Dipropionate: Inhaled Glucocorticoid

Beclomethasone dipropionate (brand names Junik, Ventolair, Foster in combination with formoterol, and numerous generics) is a synthetic glucocorticoid established as inhaled therapy in respiratory medicine. It was one of the first inhaled glucocorticoids (ICS) that changed long-term asthma therapy in the early 1970s. In Germany, beclomethasone dipropionate is available as metered dose aerosol, powder inhaler, and in fixed combinations with long-acting beta 2 agonists. Topical application to the bronchial mucosa uses the anti-inflammatory effect locally with significantly lower systemic burden than oral steroids.

The substance is a prodrug: beclomethasone dipropionate is activated by esterases in the lung to beclomethasone 17-monopropionate, the actual pharmacologically active metabolite. This activation occurs selectively in the airways, which supports the local site of action. In clinical practice, beclomethasone is often compared with modern ICS substances such as budesonide, fluticasone, or mometasone. For many patients, it remains a very effective and cost-effective option, especially in extra-fine aerosols that achieve better lung deposition.

Mechanism of Action

After activation, beclomethasone dipropionate binds to the intracellular glucocorticoid receptor in bronchial mucosal cells. The activated receptor migrates to the cell nucleus and influences gene expression. The anti-inflammatory effect is based on the inhibition of pro-inflammatory mediators such as cytokines, chemokines, prostaglandins, and leukotrienes, as well as the induction of anti-inflammatory proteins such as annexin 1.

Clinically, these effects manifest in a reduction of airway inflammation, a decrease in bronchial hyperresponsiveness, and an improvement in lung function. The effect builds up over days to weeks. Inhaled glucocorticoid therapy is the central pillar of asthma therapy from step 2 onwards and is part of COPD therapy in patients with frequent exacerbations.

Oral bioavailability is low because most of the dose is eliminated hepatically through first-pass effect. When inhaled, depending on the inhalation device, 30 to 60 percent of the dose reaches the lung, the rest is swallowed and eliminated systemically. The half-life of the active metabolite is approximately three hours. Extra-fine formulations (HFA aerosols) reach smaller airways and thus achieve more favorable lung deposition.

Indications

• Asthma bronchiale from step 2 onwards as maintenance therapy, alone or in combination with long-acting beta 2 agonists
• Chronic obstructive pulmonary disease (COPD) in patients with frequent exacerbations and FEV1 below 50 percent
• Allergic rhinitis as nasal spray, supplementary to lifestyle measures
• Adjuvant in asthma SMART therapy, in combination with formoterol as maintenance and reliever medication
• Eosinophilic bronchial disease in specialized pulmonology settings

Beclomethasone dipropionate is not suitable for acute therapy of asthma attacks. Here, short-acting beta 2 agonists such as salbutamol are the first-line choice, supplemented with systemic glucocorticoids in moderate to severe exacerbation.

Dosage and Administration

Asthma Adults: with classical aerosols 200 to 400 µg twice daily as single inhalations, maintenance dose 100 to 800 µg per day divided into two to four administrations. With extra-fine aerosols, 100 µg corresponds to approximately 200 µg of classical formulation due to better lung deposition.

COPD Adults: 200 µg twice daily, in fixed combination with formoterol or tiotropium according to step-wise plan.

Pediatric: from 5 years of age 50 to 100 µg twice daily, individual adjustment based on asthma control and growth monitoring.

Administration technique: metered dose aerosols are shaken before each actuation. Inhalation should be slow and deep followed by breath-holding for 5 to 10 seconds. Spacers (holding chambers) improve lung deposition and significantly reduce oral deposition, especially in children and elderly patients. Powder inhalers require a quick deep breath.

Rinsing mouth after inhalation: rinsing with water or brushing teeth reduces the risk of oral thrush and hoarseness.

Renal insufficiency and hepatic insufficiency: dose adjustment generally not required. Caution with severe hepatic insufficiency due to slowed metabolism.

Side Effects

Common: hoarseness, oral thrush (oral candidiasis), cough and brief bronchial irritation after inhalation.

Occasional: skin bleeding and thinner skin, headaches, sleep disturbances, slight growth retardation in children under long-term therapy.

Rare: systemic glucocorticoid side effects such as Cushing syndrome, hyperglycemia, osteoporosis, glaucoma, or cataract, especially with high doses over a long period.

Paradoxical bronchospasm: very rare immediately after inhalation, then immediate discontinuation and switch to another substance.

Hypersensitivity: rash, pruritus, very rarely anaphylaxis.

In children: regular growth monitoring, because high-dose ICS can cause small but measurable growth retardation in studies. With long-term stable asthma control, children usually catch up with growth.

Drug Interactions

• Strong CYP3A4 inhibitors (itraconazole, ketoconazole, ritonavir, clarithromycin): increase systemic levels and risk of Cushing syndrome, especially with high ICS doses.
• Beta 2 agonists (salbutamol, formoterol, salmeterol, olodaterol): synergistic effect desired, often used in fixed combinations.
• Anticholinergics (tiotropium, glycopyrronium, aclidinium): complementary therapy in COPD.
• Theophylline: potassium-lowering effect enhanced together with beta 2 agonists, electrolyte monitoring.
• Diuretics: additional hypokalemia possible, especially with combined beta 2 agonist use.
• Live vaccines: caution with high-dose ICS and systemic comedication, generally unproblematic in standard doses.

Special Precautions

Pregnancy: ICS are considered safe in pregnancy and are established because poorly controlled asthma therapy poses greater risk to pregnancy than the medication. Breastfeeding: no clinically relevant transfer into breast milk, breastfeeding during therapy is unproblematic.

Children: established from 5 years of age, younger children with spacer and mask on an individual basis.

Elderly patients: caution regarding bone metabolism, regular bone mineral density, and if necessary calcium and vitamin D supplementation.

Before starting therapy: confirm asthma diagnosis or COPD, train inhalation technique, discuss sleep hygiene and trigger avoidance, check vaccination status (influenza, pneumococcal), in children document growth baseline.

Medication adherence: ICS must be taken regularly because their effect builds up over days to weeks. Sporadic use is not effective. Patients benefit from a written asthma action plan with clear steps.

When to see a doctor: with increasing shortness of breath, frequent reliever use, nocturnal cough, activity limitation, or oxygen requirement, seek immediate medical attention. A deterioration may require therapy adjustment.

Ability to drive: generally not restricted.

You may also be interested in

• Budesonide, another inhaled glucocorticoid for asthma and COPD
• Formoterol, long-acting beta 2 agonist as combination partner
• Salbutamol, short-acting beta 2 agonist as reliever medication
• Montelukast, leukotriene receptor antagonist as add-on
• Olodaterol, ultra-long-acting beta 2 agonist in COPD

Frequently Asked Questions

Sources

• Gelbe Liste, Beclomethasone Active Ingredient Profile
• BfArM, Federal Institute for Drugs and Medical Devices
• AWMF, National Care Guideline for Asthma and COPD
• GOLD Initiative, COPD Recommendations